- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT02671968
Real-Time Continuous Glucose Monitoring (RT-CGM) in Patients With Type 1 Diabetes at High Risk for Low Glucose Values Using Multiple Daily Injections (MDI) in Germany (HYPODE-STUDY)
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
In a randomized controlled trial the primary hypothesis is tested if the usage of RT-CGM in the intervention group (CGM group) reduces the frequency of glucose values <55 mg/dl in patients with hypoglycemia problems (hypoglycemia unawareness or documented previous severe hypoglycemia) significantly more than in the control group receiving usual care (without CGM).
Secondary is tested if patients in the CGM group showed a significantly more favorable change in the below defined secondary endpoint than patients in the control group after 26 weeks follow up.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
-
Aschaffenburg, Tyskland
- Gemeinschaftspraxis Dres. Klausmann
-
Bad Heilbrunn, Tyskland
- m&i-Fachklinik Bad Heilbrunn
-
Bad Mergentheim, Tyskland
- Forschungsinstitut Diabetes-Akademie Bad Mergentheim (FIDAM)
-
Bergheim, Tyskland
- Diabetologische Schwerpunktpraxis
-
Berlin, Tyskland
- Medicover Berlin-Mitte
-
Duisburg, Tyskland
- Diabetologikum Duisburg
-
Essen, Tyskland
- Diabetes Praxis Essen
-
Essen, Tyskland
- Diabetologische Schwerpunktpraxis mit Fußambulanz
-
Hamburg, Tyskland
- Zentrum für Diabetologie Bergedorf
-
Leverkusen, Tyskland
- Gemeinschaftspraxis Dres. Kaltheuner
-
Marktredwitz, Tyskland, 95615
- Diabetes Schwerpunkt Praxis Zentrum für Hormone und Stoffwechsel
-
Münster, Tyskland, 48153
- Schwerpunktpraxis für Diabetes und Ernährungsmedizin
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Patients with type 1 diabetes for at least 12 months on multiple daily injections (MDI). MDI is defined as prandial insulin injections at each major meal (excludes pre-mixed insulin) with doses determined by SMBG and carbohydrate counting, and basal insulin injection(s)
- Age ≥ 18 years
- HbA1c ≤ 9.0 % performed within 4 months before begin of the study
- High risk for severe hypoglycemia (defined as a score of 4 or higher on the Hypoglycemia unawareness scale (HUS) or a history of at least one severe hypoglycemic event in the last 12 months (required third part assistance, not able to treat themselves))
- Willing to not use paracetamol or drugs containing it
- Signed and dated Informed Consent Form
Exclusion Criteria:
- Use of personal real-time-CGM 3 months prior to study entry and during the study (except study devices)
- Use of a flash-glucose monitoring system 3 months prior to study and during the study
- Alcoholism or drug abuse
- Unable to comply with the protocol at the investigators discretion, such as known psychiatric diagnosis, cognitive / physical decline
- Pregnancy or lactation period
- Severe known allergies, e.g. against plaster
- Mental incapacity or language barriers precluding adequate compliance with the study procedures
- Limited or no legal capacity or legal guardianship
- Dependency from the sponsor or the clinical investigator (e.g. co-workers of the sponsor or the clinical research center or their families)
- Participation in another study at the same time with a non-approved drug or a non-CE-labelled medical device.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Ingen indgriben: Kontrolgruppe
|
|
Eksperimentel: CGM group
|
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
Change in the total number of low glucose events (<55 mg/dl), between baseline and outcome phase (week 22-26) in CGM group and control group (change = subtracting number of follow up events from number of baseline events
Tidsramme: For each subject, the experimental phase has an expected duration of up to 7 months
|
For each subject, the experimental phase has an expected duration of up to 7 months
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Norbert Hermanns, Prof., Forschungsinstitut Diabetes-Akademie Bad Mergentheim (FIDAM)
Publikationer og nyttige links
Generelle publikationer
- Hermanns N, Ehrmann D, Heinemann L, Freckmann G, Waldenmaier D, Calhoun P. Real-Time Continuous Glucose Monitoring Can Predict Severe Hypoglycemia in People with Type 1 Diabetes: Combined Analysis of the HypoDE and DIAMOND Trials. Diabetes Technol Ther. 2022 Sep;24(9):603-610. doi: 10.1089/dia.2022.0130. Epub 2022 Jun 10.
- Waldenmaier D, Freckmann G, Pleus S, Hermanns N, Ehrmann D, Heinemann L, Haug C. Therapy adjustments in people with type 1 diabetes with impaired hypoglycemia awareness on multiple daily injections using real-time continuous glucose monitoring: a mechanistic analysis of the HypoDE study. BMJ Open Diabetes Res Care. 2021 Apr;9(1):e001848. doi: 10.1136/bmjdrc-2020-001848.
- Heinemann L, Freckmann G, Ehrmann D, Faber-Heinemann G, Guerra S, Waldenmaier D, Hermanns N. Real-time continuous glucose monitoring in adults with type 1 diabetes and impaired hypoglycaemia awareness or severe hypoglycaemia treated with multiple daily insulin injections (HypoDE): a multicentre, randomised controlled trial. Lancet. 2018 Apr 7;391(10128):1367-1377. doi: 10.1016/S0140-6736(18)30297-6. Epub 2018 Feb 16.
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- IDT-1510-SI / HypoDE
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Kontinuerligt glukoseovervågningssystem
-
Abbott Diabetes CareLiverpool University Hospitals NHS Foundation Trust; NHS Lothian; Cardiff... og andre samarbejdspartnereAfsluttetDiabetes mellitusDet Forenede Kongerige
-
Barnev LtdAfsluttetArbejdskraft | ObstetrikIsrael
-
Abbott Diabetes CareAfsluttetDiabetes mellitusForenede Stater
-
Medical University of ViennaRekrutteringGraviditetskomplikationer | Blodsukker | Svangerskabsdiabetes | GDM | CgmØstrig
-
Medical Research Foundation, The NetherlandsMedtronicAfsluttetGlukosemetabolismeforstyrrelser | Perioperativ plejeHolland
-
University Hospital Bispebjerg and FrederiksbergZealand University Hospital; Rigshospitalet, Denmark; Steno Diabetes Center...RekrutteringDiabetes mellitus | Dysglykæmi | Perioperativ komplikation | Kredsløb; KomplikationerDanmark
-
Christian S. MeyhoffZealand University Hospital; Rigshospitalet, Denmark; Steno Diabetes Center...Ikke rekrutterer endnuEffekten af kontinuerlig glukosemonitorering hos kirurgiske patienter med diabetes. (WARD-glucose)Diabetes mellitus | Dysglykæmi | Perioperativ komplikationDanmark
-
Norwegian University of Science and TechnologyNorwegian Diabetes AssociationAfsluttetBrug af kontinuerligt glukoseovervågningssystem i realtid hos patienter med type 1-diabetes mellitusDiabetes mellitus, type 1Norge
-
Beijing Tsinghua Chang Gung HospitalThe First Affiliated Hospital of Anhui Medical University; Beijing Tiantan... og andre samarbejdspartnereRekrutteringOmfattende komplikationsindeksKina
-
Medical Research Foundation, The NetherlandsAfsluttetDiabetes mellitus, type 1Holland